Loading...
•
Jun 30, 2023
Day One Q2 2023 Earnings Report
Day One reported second quarter financial results and corporate progress.
Key Takeaways
Day One Biopharmaceuticals announced its second quarter 2023 financial results, highlighting the initiation of the rolling submission of the tovorafenib NDA and updated data from the FIREFLY-1 trial presented at ASCO. A public offering was completed, raising $172.5 million and extending the cash runway into 2026.
Initiated rolling submission of the tovorafenib New Drug Application (NDA) in relapsed or progressive pediatric low-grade glioma (pLGG) in May 2023.
Reported FIREFLY-1 trial results with an overall response rate (ORR) of 67% and a clinical benefit rate (CBR) of 93% in RANO-HGG evaluable patients.
Completed a $172.5 million public offering, strengthening the balance sheet and extending cash runway into 2026.
Cash, cash equivalents and short-term investments totaled $442.9 million on June 30, 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...